Industry Research Reports

Home > Reports > Chemical & Material > Global Finasteride API Market Outlook, In‑Depth Analysis & Forecast to 2031

Global Finasteride API Market Outlook, In‑Depth Analysis & Forecast to 2031

Industry: Chemical & Material

Published Date: 2025-10-22

Pages: 154 Pages

Report ld: 5198113

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

The global Finasteride API market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

Finasteride API is a 5α-reductase inhibitor and therefore an antiandrogen.[9] It works by decreasing the production of dihydrotestosterone (DHT) by about 70%, including in the prostate gland and the scalp.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Includes:

This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Finasteride API market, seamlessly integrating production capacity and sales performance across the value chain. It analyzes historical production, revenue, and sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—capacity, sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

MARKET SEGMENTATION

By Company

AMRI
Mylan
Accord Pharmaceuticals
Sterling Spa
DEAFARMA
Gadea Grupo Farmacéutico, S.L.U.
Hetero
Dr.Reddys Laboratories
Pharmaffiliates
Cipla
Henan Topfond
Khonsu International
Aurobindo Pharma

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Abrove 99% Purity
99% Purity
Under 99% Purity

Segment by Application

Pharmaceutical Industry
Research Organization
Others

biaoTi CHAPTER OUTLINE

Chapter 1: Defines the Finasteride API study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.

Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts

Chapter 3: Maps global production capacity, utilization, and market share (2020–2031), identifies efficient hubs, reveals regulatory/trade policy impacts and bottlenecks.

Chapter 4: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.

Chapter 5: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks

Chapter 6: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.

Chapter 7: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.

Chapter 8: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.

Chapter 9: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.

Chapter 10: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.

Chapter 11: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles

Chapter 12: Profiles manufacturers in depth—details product specs, capacity, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.

Chapter 13: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint and technology, cost drivers, plus downstream channels and distributor roles.

Chapter 14: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.

Chapter 15: Actionable conclusions and strategic recommendations.

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:

Allocate capital strategically to high growth regions (Chapters 7–11) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 13) and customers (Chapter 6) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 4 and 12).

Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 13 and 14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Study Coverage

1.1 Introduction to Finasteride API: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Finasteride API Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Abrove 99% Purity

1.2.3 99% Purity

1.2.4 Under 99% Purity

1.3 Market Segmentation by Application

1.3.1 Global Finasteride API Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Pharmaceutical Industry

1.3.3 Research Organization

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Finasteride API Revenue Estimates and Forecasts 2020-2031

2.2 Global Finasteride API Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global Finasteride API Sales Estimates and Forecasts 2020-2031

2.4 Global Finasteride API Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Global Production Analysis

3.1 Global Finasteride API Production Capacity and Utilization Rates (2020–2031)

3.2 Regional Production: Comparative Analysis (2020 VS 2024 VS 2031)

3.3 Regional Production Dynamics

3.3.1 Historic Production by Region (2020-2025)

3.3.2 Forecasted Production by Region (2026-2031)

3.3.3 Production Market Share by Region (2020-2031)

3.3.4 Regulatory and Trade Policy Impact on Production

3.3.5 Production Capacity Enablers and Constraints

3.4 Key Regional Production Hubs

3.4.1 North America

3.4.2 Europe

3.4.3 China

3.4.4 Japan

4 Competition by Manufacturers

4.1 Global Finasteride API Sales by Manufacturers

4.1.1 Global Sales Volume by Manufacturers (2020-2025)

4.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

4.2 Global Finasteride API Manufacturer Revenue Rankings and Tiers

4.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

4.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

4.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

4.3 Manufacturer Profitability Profiles and Pricing Strategies

4.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

4.3.2 Manufacturer-Level Price Trends (2020-2025)

4.4 Key Manufacturers Manufacturing Base and Headquarters

4.5 Main Product Type Market Size by Manufacturers

4.5.1 Abrove 99% Purity Market Size by Manufacturers

4.5.2 99% Purity Market Size by Manufacturers

4.5.3 Under 99% Purity Market Size by Manufacturers

4.6 Global Finasteride API Market Concentration and Dynamics

4.6.1 Global Market Concentration (CR5 and HHI)

4.6.2 Entrant/Exit Impact Analysis

4.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

5 Global Product Segmentation Analysis

5.1 Global Finasteride API Sales Performance by Type

5.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

5.1.2 Global Sales Market Share by Type (2020-2031)

5.2 Global Finasteride API Revenue Trends by Type

5.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

5.2.2 Global Revenue Market Share by Type (2020-2031)

5.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

5.4 Product Technology Differentiation

5.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

5.5.1 High-Growth Niches and Adoption Drivers

5.5.2 Profitability Hotspots and Cost Drivers

5.5.3 Substitution Threats

6 Global Downstream Application Analysis

6.1 Global Finasteride API Sales by Application

6.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

6.1.2 Global Sales Market Share by Application (2020-2031)

6.1.3 High-Growth Application Identification

6.1.4 Emerging Application Case Studies

6.2 Global Finasteride API Revenue by Application

6.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

6.2.2 Revenue Market Share by Application (2020-2031)

6.3 Global Pricing Dynamics by Application (2020-2031)

6.4 Downstream Customer Analysis

6.4.1 Top Customers by Region

6.4.2 Top Customers by Application

7 North America

7.1 North America Sales Volume and Revenue (2020-2031)

7.2 North America Key Manufacturers Sales Revenue in 2024

7.3 North America Finasteride API Sales and Revenue by Type (2020-2031)

7.4 North America Finasteride API Sales and Revenue by Application (2020-2031)

7.5 North America Growth Accelerators and Market Barriers

7.6 North America Finasteride API Market Size by Country

7.6.1 North America Revenue by Country

7.6.2 North America Sales Trends by Country

7.6.3 US

7.6.4 Canada

7.6.5 Mexico

8 Europe

8.1 Europe Sales Volume and Revenue (2020-2031)

8.2 Europe Key Manufacturers Sales Revenue in 2024

8.3 Europe Finasteride API Sales and Revenue by Type (2020-2031)

8.4 Europe Finasteride API Sales and Revenue by Application (2020-2031)

8.5 Europe Growth Accelerators and Market Barriers

8.6 Europe Finasteride API Market Size by Country

8.6.1 Europe Revenue by Country

8.6.2 Europe Sales Trends by Country

8.6.3 Germany

8.6.4 France

8.6.5 U.K.

8.6.6 Italy

8.6.7 Russia

9 Asia-Pacific

9.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

9.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

9.3 Asia-Pacific Finasteride API Sales and Revenue by Type (2020-2031)

9.4 Asia-Pacific Finasteride API Sales and Revenue by Application (2020-2031)

9.5 Asia-Pacific Finasteride API Market Size by Region

9.5.1 Asia-Pacific Revenue by Region

9.5.2 Asia-Pacific Sales Trends by Region

9.6 Asia-Pacific Growth Accelerators and Market Barriers

9.7 Southeast Asia

9.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

9.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand

9.8 China

9.9 Japan

9.10 South Korea

9.11 China Taiwan

9.12 India

10 Central and South America

10.1 Central and South America Sales Volume and Revenue (2020-2031)

10.2 Central and South America Key Manufacturers Sales Revenue in 2024

10.3 Central and South America Finasteride API Sales and Revenue by Type (2020-2031)

10.4 Central and South America Finasteride API Sales and Revenue by Application (2020-2031)

10.5 Central and South America Investment Opportunities and Key Challenges

10.6 Central and South America Finasteride API Market Size by Country

10.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 Brazil

10.6.3 Argentina

11 Middle East and Africa

11.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

11.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

11.3 Middle East and Africa Finasteride API Sales and Revenue by Type (2020-2031)

11.4 Middle East and Africa Finasteride API Sales and Revenue by Application (2020-2031)

11.5 Middle East and Africa Investment Opportunities and Key Challenges

11.6 Middle East and Africa Finasteride API Market Size by Country

11.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

11.6.2 GCC Countries

11.6.3 Turkey

11.6.4 Egypt

11.6.5 South Africa

12 Corporate Profile

12.1 AMRI

12.1.1 AMRI Corporation Information

12.1.2 AMRI Business Overview

12.1.3 AMRI Finasteride API Product Models, Descriptions and Specifications

12.1.4 AMRI Finasteride API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.1.5 AMRI Finasteride API Sales by Product in 2024

12.1.6 AMRI Finasteride API Sales by Application in 2024

12.1.7 AMRI Finasteride API Sales by Geographic Area in 2024

12.1.8 AMRI Finasteride API SWOT Analysis

12.1.9 AMRI Recent Developments

12.2 Mylan

12.2.1 Mylan Corporation Information

12.2.2 Mylan Business Overview

12.2.3 Mylan Finasteride API Product Models, Descriptions and Specifications

12.2.4 Mylan Finasteride API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.2.5 Mylan Finasteride API Sales by Product in 2024

12.2.6 Mylan Finasteride API Sales by Application in 2024

12.2.7 Mylan Finasteride API Sales by Geographic Area in 2024

12.2.8 Mylan Finasteride API SWOT Analysis

12.2.9 Mylan Recent Developments

12.3 Accord Pharmaceuticals

12.3.1 Accord Pharmaceuticals Corporation Information

12.3.2 Accord Pharmaceuticals Business Overview

12.3.3 Accord Pharmaceuticals Finasteride API Product Models, Descriptions and Specifications

12.3.4 Accord Pharmaceuticals Finasteride API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.3.5 Accord Pharmaceuticals Finasteride API Sales by Product in 2024

12.3.6 Accord Pharmaceuticals Finasteride API Sales by Application in 2024

12.3.7 Accord Pharmaceuticals Finasteride API Sales by Geographic Area in 2024

12.3.8 Accord Pharmaceuticals Finasteride API SWOT Analysis

12.3.9 Accord Pharmaceuticals Recent Developments

12.4 Sterling Spa

12.4.1 Sterling Spa Corporation Information

12.4.2 Sterling Spa Business Overview

12.4.3 Sterling Spa Finasteride API Product Models, Descriptions and Specifications

12.4.4 Sterling Spa Finasteride API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.4.5 Sterling Spa Finasteride API Sales by Product in 2024

12.4.6 Sterling Spa Finasteride API Sales by Application in 2024

12.4.7 Sterling Spa Finasteride API Sales by Geographic Area in 2024

12.4.8 Sterling Spa Finasteride API SWOT Analysis

12.4.9 Sterling Spa Recent Developments

12.5 DEAFARMA

12.5.1 DEAFARMA Corporation Information

12.5.2 DEAFARMA Business Overview

12.5.3 DEAFARMA Finasteride API Product Models, Descriptions and Specifications

12.5.4 DEAFARMA Finasteride API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.5.5 DEAFARMA Finasteride API Sales by Product in 2024

12.5.6 DEAFARMA Finasteride API Sales by Application in 2024

12.5.7 DEAFARMA Finasteride API Sales by Geographic Area in 2024

12.5.8 DEAFARMA Finasteride API SWOT Analysis

12.5.9 DEAFARMA Recent Developments

12.6 Gadea Grupo Farmacéutico, S.L.U.

12.6.1 Gadea Grupo Farmacéutico, S.L.U. Corporation Information

12.6.2 Gadea Grupo Farmacéutico, S.L.U. Business Overview

12.6.3 Gadea Grupo Farmacéutico, S.L.U. Finasteride API Product Models, Descriptions and Specifications

12.6.4 Gadea Grupo Farmacéutico, S.L.U. Finasteride API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.6.5 Gadea Grupo Farmacéutico, S.L.U. Recent Developments

12.7 Hetero

12.7.1 Hetero Corporation Information

12.7.2 Hetero Business Overview

12.7.3 Hetero Finasteride API Product Models, Descriptions and Specifications

12.7.4 Hetero Finasteride API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.7.5 Hetero Recent Developments

12.8 Dr.Reddys Laboratories

12.8.1 Dr.Reddys Laboratories Corporation Information

12.8.2 Dr.Reddys Laboratories Business Overview

12.8.3 Dr.Reddys Laboratories Finasteride API Product Models, Descriptions and Specifications

12.8.4 Dr.Reddys Laboratories Finasteride API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.8.5 Dr.Reddys Laboratories Recent Developments

12.9 Pharmaffiliates

12.9.1 Pharmaffiliates Corporation Information

12.9.2 Pharmaffiliates Business Overview

12.9.3 Pharmaffiliates Finasteride API Product Models, Descriptions and Specifications

12.9.4 Pharmaffiliates Finasteride API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.9.5 Pharmaffiliates Recent Developments

12.10 Cipla

12.10.1 Cipla Corporation Information

12.10.2 Cipla Business Overview

12.10.3 Cipla Finasteride API Product Models, Descriptions and Specifications

12.10.4 Cipla Finasteride API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.10.5 Cipla Recent Developments

12.11 Henan Topfond

12.11.1 Henan Topfond Corporation Information

12.11.2 Henan Topfond Business Overview

12.11.3 Henan Topfond Finasteride API Product Models, Descriptions and Specifications

12.11.4 Henan Topfond Finasteride API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.11.5 Henan Topfond Recent Developments

12.12 Khonsu International

12.12.1 Khonsu International Corporation Information

12.12.2 Khonsu International Business Overview

12.12.3 Khonsu International Finasteride API Product Models, Descriptions and Specifications

12.12.4 Khonsu International Finasteride API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.12.5 Khonsu International Recent Developments

12.13 Aurobindo Pharma

12.13.1 Aurobindo Pharma Corporation Information

12.13.2 Aurobindo Pharma Business Overview

12.13.3 Aurobindo Pharma Finasteride API Product Models, Descriptions and Specifications

12.13.4 Aurobindo Pharma Finasteride API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.13.5 Aurobindo Pharma Recent Developments

13 Value Chain and Supply-Chain Analysis

13.1 Finasteride API Industry Chain

13.2 Finasteride API Upstream Materials Analysis

13.2.1 Raw Materials

13.2.2 Key Suppliers Market Share & Risk Assessment

13.3 Finasteride API Integrated Production Analysis

13.3.1 Manufacturing Footprint Analysis

13.3.2 Production Technology Overview

13.3.3 Regional Cost Drivers

13.4 Finasteride API Sales Channels and Distribution Networks

13.4.1 Sales Channels

13.4.2 Distributors

14 Finasteride API Market Dynamics

14.1 Industry Trends and Evolution

14.2 Market Growth Drivers and Emerging Opportunities

14.3 Market Challenges, Risks, and Restraints

15 Key Findings in the Global Finasteride API Study

16 Appendix

16.1 Research Methodology

16.1.1 Methodology/Research Approach

16.1.1.1 Research Programs/Design

16.1.1.2 Market Size Estimation

16.1.1.3 Market Breakdown and Data Triangulation

16.1.2 Data Source

16.1.2.1 Secondary Sources

16.1.2.2 Primary Sources

16.2 Author Details

TABLE OF FIGURES

List of Tables

Table 1. Global Finasteride API Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Finasteride API Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Finasteride API Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Finasteride API Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Finasteride API Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global Finasteride API Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)

Table 7. Global Finasteride API Sales by Region (2020-2025) & (Tons)

Table 8. Global Finasteride API Sales by Region (2026-2031) & (Tons)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global Finasteride API Production Growth Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)

Table 11. Global Finasteride API Production by Region (2020-2025) & (Tons)

Table 12. Global Finasteride API Production by Region (2026-2031) & (Tons)

Table 13. Global Finasteride API Sales by Manufacturers (2020-2025) & (Tons)

Table 14. Global Finasteride API Sales Share by Manufacturers (2020-2025)

Table 15. Global Finasteride API Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 16. Global Finasteride API Revenue Market Share by Manufacturers (2020-2025)

Table 17. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 18. Global Finasteride API by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Finasteride API as of 2024)

Table 19. Global Finasteride API Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 20. Global Finasteride API Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Ton)

Table 21. Key Manufacturers Finasteride API Manufacturing Base and Headquarters

Table 22. Global Finasteride API Market Concentration Ratio (CR5 and HHI)

Table 23. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 24. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 25. Global Finasteride API Sales by Type (2020-2025) & (Tons)

Table 26. Global Finasteride API Sales by Type (2026-2031) & (Tons)

Table 27. Global Finasteride API Revenue by Type (2020-2025) & (US$ Million)

Table 28. Global Finasteride API Revenue by Type (2026-2031) & (US$ Million)

Table 29. Global Finasteride API ASP by Type (2020-2031) & (US$/Ton)

Table 30. Technical Specifications by Key Product Type

Table 31. Global Finasteride API Sales by Application (2020-2025) & (Tons)

Table 32. Global Finasteride API Sales by Application (2026-2031) & (Tons)

Table 33. Finasteride API High-Growth Sectors Demand CAGR (2024-2031)

Table 34. Global Finasteride API Revenue by Application (2020-2025) & (US$ Million)

Table 35. Global Finasteride API Revenue by Application (2026-2031) & (US$ Million)

Table 36. Global Finasteride API ASP by Application (2020-2031) & (US$/Ton)

Table 37. Top Customers by Region

Table 38. Top Customers by Application

Table 39. North America Finasteride API Growth Accelerators and Market Barriers

Table 40. North America Finasteride API Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 41. North America Finasteride API Sales (Tons) by Country (2020 VS 2024 VS 2031)

Table 42. Europe Finasteride API Growth Accelerators and Market Barriers

Table 43. Europe Finasteride API Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 44. Europe Finasteride API Sales (Tons) by Country (2020 VS 2024 VS 2031)

Table 45. Asia-Pacific Finasteride API Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Asia-Pacific Finasteride API Sales (Tons) by Country (2020 VS 2024 VS 2031)

Table 47. Asia-Pacific Finasteride API Growth Accelerators and Market Barriers

Table 48. Southeast Asia Finasteride API Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 49. Central and South America Finasteride API Investment Opportunities and Key Challenges

Table 50. Central and South America Finasteride API Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 51. Middle East and Africa Finasteride API Investment Opportunities and Key Challenges

Table 52. Middle East and Africa Finasteride API Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 53. AMRI Corporation Information

Table 54. AMRI Description and Major Businesses

Table 55. AMRI Product Models, Descriptions and Specifications

Table 56. AMRI Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 57. AMRI Sales Value Proportion by Product in 2024

Table 58. AMRI Sales Value Proportion by Application in 2024

Table 59. AMRI Sales Value Proportion by Geographic Area in 2024

Table 60. AMRI Finasteride API SWOT Analysis

Table 61. AMRI Recent Developments

Table 62. Mylan Corporation Information

Table 63. Mylan Description and Major Businesses

Table 64. Mylan Product Models, Descriptions and Specifications

Table 65. Mylan Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 66. Mylan Sales Value Proportion by Product in 2024

Table 67. Mylan Sales Value Proportion by Application in 2024

Table 68. Mylan Sales Value Proportion by Geographic Area in 2024

Table 69. Mylan Finasteride API SWOT Analysis

Table 70. Mylan Recent Developments

Table 71. Accord Pharmaceuticals Corporation Information

Table 72. Accord Pharmaceuticals Description and Major Businesses

Table 73. Accord Pharmaceuticals Product Models, Descriptions and Specifications

Table 74. Accord Pharmaceuticals Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 75. Accord Pharmaceuticals Sales Value Proportion by Product in 2024

Table 76. Accord Pharmaceuticals Sales Value Proportion by Application in 2024

Table 77. Accord Pharmaceuticals Sales Value Proportion by Geographic Area in 2024

Table 78. Accord Pharmaceuticals Finasteride API SWOT Analysis

Table 79. Accord Pharmaceuticals Recent Developments

Table 80. Sterling Spa Corporation Information

Table 81. Sterling Spa Description and Major Businesses

Table 82. Sterling Spa Product Models, Descriptions and Specifications

Table 83. Sterling Spa Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 84. Sterling Spa Sales Value Proportion by Product in 2024

Table 85. Sterling Spa Sales Value Proportion by Application in 2024

Table 86. Sterling Spa Sales Value Proportion by Geographic Area in 2024

Table 87. Sterling Spa Finasteride API SWOT Analysis

Table 88. Sterling Spa Recent Developments

Table 89. DEAFARMA Corporation Information

Table 90. DEAFARMA Description and Major Businesses

Table 91. DEAFARMA Product Models, Descriptions and Specifications

Table 92. DEAFARMA Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 93. DEAFARMA Sales Value Proportion by Product in 2024

Table 94. DEAFARMA Sales Value Proportion by Application in 2024

Table 95. DEAFARMA Sales Value Proportion by Geographic Area in 2024

Table 96. DEAFARMA Finasteride API SWOT Analysis

Table 97. DEAFARMA Recent Developments

Table 98. Gadea Grupo Farmacéutico, S.L.U. Corporation Information

Table 99. Gadea Grupo Farmacéutico, S.L.U. Description and Major Businesses

Table 100. Gadea Grupo Farmacéutico, S.L.U. Product Models, Descriptions and Specifications

Table 101. Gadea Grupo Farmacéutico, S.L.U. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 102. Gadea Grupo Farmacéutico, S.L.U. Recent Developments

Table 103. Hetero Corporation Information

Table 104. Hetero Description and Major Businesses

Table 105. Hetero Product Models, Descriptions and Specifications

Table 106. Hetero Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 107. Hetero Recent Developments

Table 108. Dr.Reddys Laboratories Corporation Information

Table 109. Dr.Reddys Laboratories Description and Major Businesses

Table 110. Dr.Reddys Laboratories Product Models, Descriptions and Specifications

Table 111. Dr.Reddys Laboratories Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 112. Dr.Reddys Laboratories Recent Developments

Table 113. Pharmaffiliates Corporation Information

Table 114. Pharmaffiliates Description and Major Businesses

Table 115. Pharmaffiliates Product Models, Descriptions and Specifications

Table 116. Pharmaffiliates Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 117. Pharmaffiliates Recent Developments

Table 118. Cipla Corporation Information

Table 119. Cipla Description and Major Businesses

Table 120. Cipla Product Models, Descriptions and Specifications

Table 121. Cipla Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 122. Cipla Recent Developments

Table 123. Henan Topfond Corporation Information

Table 124. Henan Topfond Description and Major Businesses

Table 125. Henan Topfond Product Models, Descriptions and Specifications

Table 126. Henan Topfond Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 127. Henan Topfond Recent Developments

Table 128. Khonsu International Corporation Information

Table 129. Khonsu International Description and Major Businesses

Table 130. Khonsu International Product Models, Descriptions and Specifications

Table 131. Khonsu International Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 132. Khonsu International Recent Developments

Table 133. Aurobindo Pharma Corporation Information

Table 134. Aurobindo Pharma Description and Major Businesses

Table 135. Aurobindo Pharma Product Models, Descriptions and Specifications

Table 136. Aurobindo Pharma Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 137. Aurobindo Pharma Recent Developments

Table 138. Key Raw Materials Distribution

Table 139. Raw Materials Key Suppliers

Table 140. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 141. Milestones in Production Technology Evolution

Table 142. Distributors List

Table 143. Market Trends and Market Evolution

Table 144. Market Drivers and Opportunities

Table 145. Market Challenges, Risks, and Restraints

Table 146. Research Programs/Design for This Report

Table 147. Key Data Information from Secondary Sources

Table 148. Key Data Information from Primary Sources

List of Figures

Figure 1. Finasteride API Product Picture

Figure 2. Global Finasteride API Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Abrove 99% Purity Product Picture

Figure 4. 99% Purity Product Picture

Figure 5. Under 99% Purity Product Picture

Figure 6. Global Finasteride API Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 7. Pharmaceutical Industry

Figure 8. Research Organization

Figure 9. Others

Figure 10. Finasteride API Report Years Considered

Figure 11. Global Finasteride API Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 12. Global Finasteride API Revenue (2020-2031) & (US$ Million)

Figure 13. Global Finasteride API Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 14. Global Finasteride API Revenue Market Share by Region (2020-2031)

Figure 15. Global Finasteride API Sales (2020-2031) & (Tons)

Figure 16. Global Finasteride API Sales (CAGR) by Region (2020-2031) (Tons)

Figure 17. Global Finasteride API Sales Market Share by Region (2020-2031)

Figure 18. Global Finasteride API Capacity, Production and Utilization (2020-2031) & (Tons)

Figure 19. Global Finasteride API Production Trend by Region (2020-2031) (Tons)

Figure 20. Global Finasteride API Production Market Share by Region (2020-2031)

Figure 21. Production Capacity Enablers & Constraints

Figure 22. Finasteride API Production Growth Rate in North America (2020-2031) & (Tons)

Figure 23. Finasteride API Production Growth Rate in Europe (2020-2031) & (Tons)

Figure 24. Finasteride API Production Growth Rate in China (2020-2031) & (Tons)

Figure 25. Finasteride API Production Growth Rate in Japan (2020-2031) & (Tons)

Figure 26. Top 5 and Top 10 Manufacturers Finasteride API Sales Volume Market Share in 2024

Figure 27. Global Finasteride API Revenue Market Share Ranking (2024)

Figure 28. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 29. Abrove 99% Purity Revenue Market Share by Manufacturer in 2024

Figure 30. 99% Purity Revenue Market Share by Manufacturer in 2024

Figure 31. Under 99% Purity Revenue Market Share by Manufacturer in 2024

Figure 32. Type Eight Revenue Market Share by Manufacturer in 2024

Figure 33. Type Nine Revenue Market Share by Manufacturer in 2024

Figure 34. Global Finasteride API Sales Market Share by Type (2020-2031)

Figure 35. Global Finasteride API Revenue Market Share by Type (2020-2031)

Figure 36. Global Finasteride API Sales Market Share by Application (2020-2031)

Figure 37. Global Finasteride API Revenue Market Share by Application (2020-2031)

Figure 38. North America Finasteride API Sales YoY (2020-2031) & (Tons)

Figure 39. North America Finasteride API Revenue YoY (2020-2031) & (US$ Million)

Figure 40. North America Top 5 Manufacturers Finasteride API Sales Revenue (US$ Million) in 2024

Figure 41. North America Finasteride API Sales Volume (Tons) by Type (2020- 2031)

Figure 42. North America Finasteride API Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 43. North America Finasteride API Sales Volume (Tons) by Application (2020-2031)

Figure 44. North America Finasteride API Sales Revenue (US$ Million) by Application (2020-2031)

Figure 45. US Finasteride API Revenue (2020-2031) & (US$ Million)

Figure 46. Canada Finasteride API Revenue (2020-2031) & (US$ Million)

Figure 47. Mexico Finasteride API Revenue (2020-2031) & (US$ Million)

Figure 48. Europe Finasteride API Sales YoY (2020-2031) & (Tons)

Figure 49. Europe Finasteride API Revenue YoY (2020-2031) & (US$ Million)

Figure 50. Europe Top 5 Manufacturers Finasteride API Sales Revenue (US$ Million) in 2024

Figure 51. Europe Finasteride API Sales Volume (Tons) by Type (2020-2031)

Figure 52. Europe Finasteride API Sales Revenue (US$ Million) by Type (2020-2031)

Figure 53. Europe Finasteride API Sales Volume (Tons) by Application (2020-2031)

Figure 54. Europe Finasteride API Sales Revenue (US$ Million) by Application (2020-2031)

Figure 55. Germany Finasteride API Revenue (2020-2031) & (US$ Million)

Figure 56. France Finasteride API Revenue (2020-2031) & (US$ Million)

Figure 57. U.K. Finasteride API Revenue (2020-2031) & (US$ Million)

Figure 58. Italy Finasteride API Revenue (2020-2031) & (US$ Million)

Figure 59. Russia Finasteride API Revenue (2020-2031) & (US$ Million)

Figure 60. Asia-Pacific Finasteride API Sales YoY (2020-2031) & (Tons)

Figure 61. Asia-Pacific Finasteride API Revenue YoY (2020-2031) & (US$ Million)

Figure 62. Asia-Pacific Top 8 Manufacturers Finasteride API Sales Revenue (US$ Million) in 2024

Figure 63. Asia-Pacific Finasteride API Sales Volume (Tons) by Type (2020- 2031)

Figure 64. Asia-Pacific Finasteride API Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 65. Asia-Pacific Finasteride API Sales Volume (Tons) by Application (2020-2031)

Figure 66. Asia-Pacific Finasteride API Sales Revenue (US$ Million) by Application (2020-2031)

Figure 67. Indonesia Finasteride API Revenue (2020-2031) & (US$ Million)

Figure 68. Japan Finasteride API Revenue (2020-2031) & (US$ Million)

Figure 69. South Korea Finasteride API Revenue (2020-2031) & (US$ Million)

Figure 70. China Taiwan Finasteride API Revenue (2020-2031) & (US$ Million)

Figure 71. India Finasteride API Revenue (2020-2031) & (US$ Million)

Figure 72. Central and South America Finasteride API Sales YoY (2020-2031) & (Tons)

Figure 73. Central and South America Finasteride API Revenue YoY (2020-2031) & (US$ Million)

Figure 74. Central and South America Top 5 Manufacturers Finasteride API Sales Revenue (US$ Million) in 2024

Figure 75. Central and South America Finasteride API Sales Volume (Tons) by Type (2021-2031)

Figure 76. Central and South America Finasteride API Sales Revenue (US$ Million) by Type (2020-2031)

Figure 77. Central and South America Finasteride API Sales Volume (Tons) by Application (2020-2031)

Figure 78. Central and South America Finasteride API Sales Revenue (US$ Million) by Application (2020-2031)

Figure 79. Brazil Finasteride API Revenue (2020-2025) & (US$ Million)

Figure 80. Argentina Finasteride API Revenue (2020-2025) & (US$ Million)

Figure 81. Middle East, and Africa Finasteride API Sales YoY (2020-2031) & (Tons)

Figure 82. Middle East and Africa Finasteride API Revenue YoY (2020-2031) & (US$ Million)

Figure 83. Middle East and Africa Top 5 Manufacturers Finasteride API Sales Revenue (US$ Million) in 2024

Figure 84. Middle East and Africa Finasteride API Sales Volume (Tons) by Type (2021-2031)

Figure 85. South America Finasteride API Sales Revenue (US$ Million) by Type (2020-2031)

Figure 86. Middle East and Africa Finasteride API Sales Volume (Tons) by Application (2020-2031)

Figure 87. Middle East and Africa Finasteride API Sales Revenue (US$ Million) by Application (2020-2031)

Figure 88. GCC Countries Finasteride API Revenue (2020-2025) & (US$ Million)

Figure 89. Turkey Finasteride API Revenue (2020-2025) & (US$ Million)

Figure 90. Egypt Finasteride API Revenue (2020-2025) & (US$ Million)

Figure 91. South Africa Finasteride API Revenue (2020-2025) & (US$ Million)

Figure 92. Finasteride API Industry Chain Mapping

Figure 93. Regional Finasteride API Manufacturing Base Distribution (%)

Figure 94. Finasteride API Production Process

Figure 95. Regional Finasteride API Production Cost Structure

Figure 96. Channels of Distribution (Direct Vs Distribution)

Figure 97. Bottom-up and Top-down Approaches for This Report

Figure 98. Data Triangulation

Figure 99. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Finasteride API market? zhanKai

The top companies in the global Finasteride API market are AMRI、Mylan、Accord Pharmaceuticals.

Related Reports

Finasteride API- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Finasteride API was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-07-14
Pages: 137
USD 3950.00
(Single User License)
Global Finasteride API Market Research Report 2026
The global Finasteride API market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-04-21
Pages: 137
USD 2900.00
(Single User License)
Finasteride API- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Finasteride API was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-15
Pages: 123
USD 3950.00
(Single User License)
Global Finasteride API Market Research Report 2025
The global market for Finasteride API was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-02-15
Pages: 99
USD 2900.00
(Single User License)
Global Finasteride API Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Finasteride API market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-15
Pages: 95
USD 4250.00
(Single User License)
Global Finasteride API Market Insights, Forecast to 2030
Finasteride API is a 5α-reductase inhibitor and therefore an antiandrogen.[9] It works by decreasing the production of dihydrotestosterone (DHT) by about 70%, including in the prostate gland and the scalp.
Published Date: 2024-04-07
Pages: 111
USD 4900.00
(Single User License)
Finasteride API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Finasteride API is a 5α-reductase inhibitor and therefore an antiandrogen.[9] It works by decreasing the production of dihydrotestosterone (DHT) by about 70%, including in the prostate gland and the scalp.
Published Date: 2024-02-19
Pages: 122
USD 3950.00
(Single User License)
Global Finasteride API Market Research Report 2024
Finasteride API is a 5α-reductase inhibitor and therefore an antiandrogen.[9] It works by decreasing the production of dihydrotestosterone (DHT) by about 70%, including in the prostate gland and the scalp.
Published Date: 2024-01-11
Pages: 97
USD 2900.00
(Single User License)

Finasteride API- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Finasteride API was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-07-14
Pages: 137
USD 3950.00 (Single User License)
Global Finasteride API Market Research Report 2026
The global Finasteride API market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-04-21
Pages: 137
USD 2900.00 (Single User License)
Finasteride API- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Finasteride API was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-15
Pages: 123
USD 3950.00 (Single User License)
Global Finasteride API Market Research Report 2025
The global market for Finasteride API was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-02-15
Pages: 99
USD 2900.00 (Single User License)
Global Finasteride API Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Finasteride API market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-15
Pages: 95
USD 4250.00 (Single User License)
Global Finasteride API Market Insights, Forecast to 2030
Finasteride API is a 5α-reductase inhibitor and therefore an antiandrogen.[9] It works by decreasing the production of dihydrotestosterone (DHT) by about 70%, including in the prostate gland and the scalp.
Published: 2024-04-07
Pages: 111
USD 4900.00 (Single User License)
Finasteride API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Finasteride API is a 5α-reductase inhibitor and therefore an antiandrogen.[9] It works by decreasing the production of dihydrotestosterone (DHT) by about 70%, including in the prostate gland and the scalp.
Published: 2024-02-19
Pages: 122
USD 3950.00 (Single User License)
Global Finasteride API Market Research Report 2024
Finasteride API is a 5α-reductase inhibitor and therefore an antiandrogen.[9] It works by decreasing the production of dihydrotestosterone (DHT) by about 70%, including in the prostate gland and the scalp.
Published: 2024-01-11
Pages: 97
USD 2900.00 (Single User License)